Current aspects of the treatment of BRCA-associated ovarian cancer


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Ovarian cancer (OC) is still the leading cause of death from oncogynecologic diseases. This article provides an up-to-date review of data on the incidence of a BRCA-associated OC. Various aspects of the treatment of patients with this disease, including features of chemotherapy for BRCA-associated OC, as well as the role and prospects for the development of new therapies, including targeted therapy and immunotherapy, are discussed. Information on the presence of BRCA1/2 gene mutations can have a significant impact on the treatment of patients with advanced OC at all stages of the treatment of patients. Further research in this area, including with the use of modern targeted and immunotherapeutic agents should contribute to the improvement of patient outcomes.

全文:

受限制的访问

作者简介

Aleksey Rumyantsev

N.N. Blokhin National Medical Research Center of Oncology

Email: alexeymma@gmail.com

参考

  1. Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные заболевания в России в 2014 году (заболеваемость и смертность). М., 2018. 250 с.
  2. Howlader N., Noone A.M., Krapcho M., et al. SEER Cancer Statistics Review, 1975-2012, based on November 2014 SEER data submission, posted to the SEER web site. April 2015.
  3. Stratton J.Fю, Pharoah P.D.P. Smith S.K., et al. A systematic review and meta-analysis of family history and risk of ovarian cancer. Br J. Obstet Gynecol. 1998;105:493.
  4. Kuchenbaecker K.B., Hopper J.L., Barnes D.R., et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317(23):2402-16.
  5. Soegaard M., Kjaer S.K., Cox M., et al. BRCA1 and BRCA2 Mutation Prevalence and Clinical Characteristics of a Population-Based Series of Ovarian Cancer Cases from Denmark. Clinical Cancer Research. Clin Cancer Res. 2008;14(12):3761-67.
  6. Satagopan J.M., Boyd J., Kauff N.D., et ai. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res. 2002;8(12):3776-81.
  7. Aisop K., et ai. BRCA mutation frequency and patterns of treatment response in BRCA mutationpositive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J. Ciin. Oncoi. 2012;30:2654-63.
  8. M0iier P., Hagen A.I., Apoid J., et al. Genetic epidemioiogy of BRCA mutations--family history detects less than 50% of the mutation carriers. Eur J Cancer. 2007;43(11):1713-17.
  9. George A., Kaye S., Banerjee S., et al. Deiivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. Nat Rev Ciin Oncoi. 2017;14(5):284-96.
  10. Pennington K.P, et al. Germline and somatic mutations in homoiogous recombination genes predict piatinum response and survivai in ovarian, fallopian tube, and peritoneal carcinomas. Clin. Cancer Res. 2014;20:764-75.
  11. Ledermann J., Harter P., Gouriey C., et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15): 1382-92.
  12. Yun M.H., Hiom K. Understanding the functions of BRCA1 in the DNA-damage response. Biochem Soc Trans. 2009;37(Pt3):597-604.
  13. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J. Clin Oncol 2008;26(22):3785-90.
  14. Farmer H., McCabe N., Lord C.J., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917-21.
  15. Konstantinopoulos P.A., Ceccaldi R., Shapiro G.I., et al. Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. Cancer Discov. 2015;5(11):1137-54.
  16. ledermann J., Harter P., Gourley C., et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8):852-61.
  17. Государственный Реестр Лекарственных Средств. Инструкция по применению лекарственного препарата для медицинского применения препарата Линпарза от 11.07.2016.
  18. Kaufman B., Shapira-Frommer R., Schmutzler R.K. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J. Clin Oncol. 2015;33(3):244-50.
  19. FDA Approves Olaparib (Lynparza) for BRCA Ovarian Cancer. Medscape. Dec 19, 2014. URL: http://www.medscape.com/viewarticle/836955.
  20. Drugs@FDA. Full Prescribing information for Olaparib (Lynparza). URL: https://www.accessdata.fda.gov/ drugsatfda_docs/label/2018/208558s001lbl.pdf.
  21. European Medicines Agency Lynparza Product information. URL: https://www.ema.europa. eu/medicines/human/EPAR/lynparza#product-information-section.
  22. European Medicines Agency Zejula Product information. URL: https://www.ema.europa.eu/ documents/product-information/zejula-epar-product-information_en.pdf.
  23. ison G., Howie L., Amiri-Kordestani L., et al. FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy Clin Cancer Res. 2018;24(17):4066-71.
  24. European Medicines Agency. Rubraca Product information. URL: https://www.ema.europa.eu/ documents/product-information/rubraca-epar-product-information_en.pdf.
  25. Drugs@FDA. Full Prescribing information for Rucaparib (Rubraca). URL: https://www. accessdata.fda.gov/drugsatfda_docs/ label/2018/209115s003lbl.pdf.
  26. Coleman R.L., Oza A.M., Lorusso D., et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARiEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;390: 1949-61.
  27. Mirza M.R., Monk B.J., Herrstedt J., et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N. Engl J. Med. 2016;375:2154-64.
  28. Pujade-Lauraine E., Ledermann J.A., Selle F., et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1274-84.
  29. NCCN Clinical Practice Guidelines. Antiemesis. Version 3.2018. June 11, 2018. URL: https:// www.nccn.org/professionals/physician_gls/pdf/ antiemesis.pdf.
  30. Gunderson C.C., Matulonis U., Moore K.N. Management of the toxicities of common targeted therapeutics for gynecologic cancers. Gynecol Oncol. 2018;148(3):591-600.
  31. Friedlander M., Gebski V., Gibbs E., et al. Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. Lancet Oncol. 2018;19(8):1126-34.
  32. Oza A.M. Matulonis U.A., Malander S., et al. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomized controlled trial. Lancet Oncol. 2018;19(8):1117-25.
  33. Ledermann J.A., Harter P., Gourley C., et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016;17(11):1579-89.
  34. Matulonis U.A., Harter P., Gourley C. Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Cancer. 2016;122(12):1844-52.
  35. Armstrong D.K., Bundy B., Wenzel L., et al. intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl J. Med. 2006;354(1):34-43.
  36. Howell S.B., Pfeifle C.L., Wung W.E. et al. intraperitoneal cisplatin with systemic thiosulfate protection. Ann intern Med. 1982;97(6):845-51.
  37. Fujiwara K., Nagao S., Aotani E., et al. Principle and evolving role of intraperitoneal chemotherapy in ovarian cancer. Expert Opin Pharmacother. 2013;14(13):1797-806.
  38. Lesnock J.L., Darcy K.M., Tian C., et al. BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study. Br J. Cancer. 2013;108(6):1231-37.
  39. Тюляндин С.А., Коломиец Л.А., Морхов К.Ю. и др. Практические рекомендации по лекарственному лечению рака яичников, первичного рака брюшины и рака маточных труб. Злокачественные опухоли: Практические рекомендации RUSSCO №3s2, 2017 (том 7). С. 135-45.
  40. NCCN Clinical Practice Guidelines. Ovarian cancer. Version 4.2017. Доступно по адресу: https:// www.nccn.org/professionals/physician_gls/PDF/ ovarian.pdf.
  41. Tan D.S., Rothermundt C., Thomas K., et al. «BRCAness» syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J. Clin Oncol. 2008;26(34):5530-36.
  42. Wang W., Zou W., Liu J.R., et al. Tumor-infiltrating T. cells in epithelial ovarian cancer: predictors of prognosis and biological basis of immunotherapy. Gynecol Oncol. 2018;151(1):1-3.
  43. Zhang L., Conejo-Garcia J.R., Katsaros D., et al. intratumoral T. Cells, Recurrence, and Survival in Epithelial Ovarian Cancer. N. Engl J. Med. 2003;348(3):203-13.
  44. Hamanishi J., Mandai M., ikeda T., et al. Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. J. Clin Oncol. 2015;33(34): 4015-22.
  45. Strickland K.C., Howitt B.E., Shukla S.A., et al. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016;7(12): 13587-98.
  46. Matsuo K., Spragg S.E., Ciccone M.A., et al. Nivolumab use for BRCA gene mutation carriers with recurrent epithelial ovarian cancer: A case series. Gynecol Oncol Rep. 2018;25:98-101.
  47. Cancer Genome Atlas Research Network. integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609-15.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2018
##common.cookie##